IYIchiro Yajima

Ichiro Yajima

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ichiro Yajima has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Preconditioning Human Skin Fibroblasts with 505 nm Blue–Green Light Reduces UVB-Induced Cyclobutane Pyrimidine Dimers

    by Nana Kanda, Sayuri Furuno, Hikaru Iwata, Nozomi Suga, Megumi Oya, Shota Suzuki, Kentaro Yamazaki, Ichiro Yajima

    Visible-light preconditioning may complement sunscreen use by enhancing intrinsic DNA damage responses. We pre-irradiated Hs27 human dermal fibroblasts with 505 nm blue–green light (5.0 mW/cm2, 3–10 min; 0.9–3.0 J/cm2) before UVB irradiation (20 mJ/cm2). At 505 nm, the residual cyclobutane pyrimidine dimer (CPD) burden measured 24 h after UVB was reduced when UVB followed immediately or after 3–24 h (with residual CPDs falling to approximately 67% of the UVB-alone level—an approximately 33% reduction—at the most effective 3.0 J/cm2, 24 h condition), whereas protection was lost by 48 h. Under the 0 h interval condition, CPDs were also quantified immediately after UVB to compare the early CPD signal with the 24 h residual endpoint; all three visible wavelengths (505, 470 and 630 nm) lowered the immediate post-UVB signal, but only 505 nm preconditioning sustained the protective effect at the 24 h endpoint. Blue light (470 nm) produced a limited delayed benefit, whereas red light (630 nm) did not confer consistent protection and increased the residual CPD burden under selected conditions. Non-toxic 505 nm exposure primed an amplified NRF2/ARE response to subsequent UVB; XPC and XPD mRNAs rose at 2–6 h, while XPA and XPB declined early. Together, these findings support further evaluation of 505 nm blue–green light as a proof-of-concept, device-oriented strategy for timed photoprotection against UVB-induced photoaging; because these findings were obtained in a single dermal fibroblast model, they will require validation in keratinocytes and more complex skin systems before any practical application.

  • Open Access

    Acyclic Retinoid Attenuates STAT3 Signaling and Reduces In Vitro Growth of A375-Derived Dabrafenib Plus Trametinib-Resistant Melanoma Cells

    by Mitsuaki Nishizawa, Masanori Kimura, Hinata Hamada, Ichiro Yajima

    Resistance to combined BRAF and MEK inhibition remains a major barrier to durable disease control in BRAF-mutant melanoma. Acyclic retinoid (ACR; peretinoin) is a clinically studied retinoid, but its activity in MAPK inhibitor-resistant melanoma remains incompletely defined. Here, we established A375P-derived dabrafenib plus trametinib-resistant clones and evaluated ACR mainly in the A375PDTR-D clone as an in vitro proof-of-concept model. Resistant clones retained higher viability and failed to suppress ERK phosphorylation under dabrafenib plus trametinib treatment. In A375PDTR-D cells, ACR reduced short-term viability and clonogenic growth and was associated with decreased STAT3 Tyr705 phosphorylation, reduced EGFR, Cyclin D1, and Cyclin B1 expression, and increased p27KIP1. ACR did not detectably suppress AKT, MEK/ERK, or basal JNK phosphorylation under the tested conditions. These findings support further investigation of ACR as a candidate non-MAPK adjunct strategy; however, generalizability to broader melanoma models, formal drug-interaction status, direct cell-cycle/apoptosis effects, clinically achievable exposure, and in vivo efficacy remain to be established.

  • Open Access

    Acyclic Retinoid Overcomes Vemurafenib Resistance in Melanoma CellsviaDual Inhibition of MAPK and PI3K/AKT/mTOR Pathways

    by Yui Suzuki, Soichiro Usuki, Mitsuaki Nishizawa, Noriyoshi Tanaka, Yoshitomo Suhara, Ichiro Yajima

    Background/Aim: To investigate the effects of acyclic retinoid (ACR) on v-raf murine sarcoma viral oncogene homolog BV600E (BRAFV600E)-mutant melanoma cells and its potential to overcome vemurafenib resistance by targeting the mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K)/AKT serine/threonine kinase 1 (AKT)/mammalian target of rapamycin (mTOR) pathways. Materials and Methods: The BRAFV600E-mutant melanoma cell lines, A375 and SK-Mel28, were treated with ACR alone or in combination with low-dose vemurafenib. Cell viability was measured and vemurafenib-resistant A375 cells (A375VR) were developed through prolonged exposure to vemurafenib. Western blotting was used to analyze the phosphorylation of extracellular-regulated kinase 1 and 2 (ERK1/2), AKT, phospho-p70 S6 kinase (p70S6K), and Eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) as well as the expression of cell cycle- and apoptosis-related proteins. Results: ACR reduced the viability of A375 and SK-Mel28 cells by inhibiting ERK1/2 phosphorylation and increasing cleavage of caspase-3. Combined treatment with ACR and low-dose vemurafenib enhanced the effects on melanoma cells. In A375VR cells, ACR reduced cell viability by inhibiting both the MAPK and PI3K/AKT/mTOR pathways, as evidenced by the reduced phosphorylation of ERK1/2, AKT, p70S6K, and 4EBP1. ACR also reduced cyclin D1 and BCL2 levels while increasing expression of cyclin-dependent kinase inhibitory protein 1 (p27KIP1). Conclusion: ACR exhibited potent anticancer effects on BRAFV600E-mutant and vemurafenib-resistant melanoma cells by dual-targeting of MAPK and PI3K/AKT/mTOR pathways, indicating its potential as a novel therapeutic agent for melanoma treatment.


  • Open Access

    Acyclic Retinoid Inhibits the EGFR/AKT Signaling Pathway and Cancels Cisplatin-resistant Cell Characteristics

    by Makito Motoyama, Ryota Shigefuku, Noriyoshi Tanaka, Mitsuaki Nishizawa, Keigo Oshio, Yoshitomo Suhara, Ichiro Yajima

    Background/Aim: Lung cancer is among the most prevalent and lethal malignancies worldwide, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. Overactivation of the EGFR/AKT signaling pathway contributes significantly to NSCLC progression and metastasis. Cisplatin, a widely used chemotherapeutic agent, faces limitations due to severe side effects and the emergence of resistant cancer cells. Acyclic retinoid (ACR), a synthetic derivative of vitamin A, has shown antitumor effects in hepatocellular carcinoma, but its efficacy against NSCLC and cisplatin-resistant cells remains unclear. This study aimed to investigate whether ACR could inhibit EGFR/AKT signaling and enhance therapeutic efficacy against NSCLC and cisplatin-resistant cells. Materials and Methods: Human NSCLC A549 cells, cisplatin-resistant A549 (A549CR) cells, and normal lung epithelial BEAS-2B cells were treated with ACR, alone or in combination with cisplatin. Cell viability, apoptosis, and changes in expression/phosphorylation of EGFR, AKT, and cell cycle regulators were assessed using cell viability assay, immunostaining, and immunoblotting. Results: ACR selectively reduced viability of A549 cells with less toxicity to BEAS-2B cells and induced apoptosis via cleaved Caspase-3 activation. ACR inhibited EGFR/AKT signaling and up-regulated p27KIP1 in A549 cells. The combination of ACR and cisplatin synergistically reduced cell viability and suppressed AKT phosphorylation. Notably, ACR also inhibited EGFR/AKT signaling in A549CR cells, restoring sensitivity to cisplatin and reversing EMT-like characteristics. Conclusion: ACR effectively inhibits EGFR/AKT signaling and enhances cisplatin sensitivity in NSCLC and cisplatin-resistant cells, suggesting its potential as a promising therapeutic strategy for lung cancer.


  • Open Access

    Anti-Graying Effects of External and Internal Treatments with Luteolin on Hair in Model Mice

    by Machiko Iida, Takumi Kagawa, Ichiro Yajima, Akihito Harusato, Akira Tazaki, Delgama A. S. M. Nishadhi, Nobuhiko Taguchi, Masashi Kato

    Little is known about the anti-graying effects of antioxidants on hair. The anti-graying effects of three antioxidants (luteolin, hesperetin, and diosmetin) on hair were investigated according to the sequential processes of hair graying that were previously clarified in model mice [Ednrb(+/−);RET-mice]. External treatment with luteolin, but not that with hesperetin or diosmetin, alleviated hair graying in Ednrb(+/−);RET-mice. Internal treatment with luteolin also mitigated hair graying in the mice. Although both luteolin treatments had very limited effects on hair cycles, the treatments suppressed the increase in p16ink4a-positive cells in bulges [senescent keratinocyte stem cells (KSCs)]. Both of the treatments also suppressed decreases in the expression levels of endothelins in KSCs and their receptor (Ednrb) in melanocyte stem cells (MSCs) and alleviated hair graying in the mice. Luteolin is a special antioxidant with an anti-graying potency through improvement of age-related dysfunction in signaling between endothelins in KSCs and their receptor in MSCs. Luteolin for topical and oral use is commercially available to people in the form of supplements. Similar processes of hair graying in Ednrb(+/−);RET-mice and humans have been reported. These results are encouraging for the practical application of luteolin as a medicine with an anti-graying effect on hair in humans.


  • Open Access

    Supplementary Figure 2 from Actin-Binding Protein, Espin: A Novel Metastatic Regulator for Melanoma

    by Takeshi Yanagishita, Ichiro Yajima, Mayuko Kumasaka, Yoshiyuki Kawamoto, Toyonori Tsuzuki, Yoshinari Matsumoto, Daisuke Watanabe, Masashi Kato

    PDF file - 32K, Transcript expression of Espin isoforms in melanocytic tumors that developed in RET-mice.

  • Open Access

    Supplementary Figure 3 from Actin-Binding Protein, Espin: A Novel Metastatic Regulator for Melanoma

    by Takeshi Yanagishita, Ichiro Yajima, Mayuko Kumasaka, Yoshiyuki Kawamoto, Toyonori Tsuzuki, Yoshinari Matsumoto, Daisuke Watanabe, Masashi Kato

    PDF file - 138K, Specification of anti-Espin-ru antibody.

  • Open Access

    Supplementary Figure 1 from Actin-Binding Protein, Espin: A Novel Metastatic Regulator for Melanoma

    by Takeshi Yanagishita, Ichiro Yajima, Mayuko Kumasaka, Yoshiyuki Kawamoto, Toyonori Tsuzuki, Yoshinari Matsumoto, Daisuke Watanabe, Masashi Kato

    PDF file - 44K, Gene maps of Espin isoforms.

  • Open Access

    Supplementary Methods from Actin-Binding Protein, Espin: A Novel Metastatic Regulator for Melanoma

    by Takeshi Yanagishita, Ichiro Yajima, Mayuko Kumasaka, Yoshiyuki Kawamoto, Toyonori Tsuzuki, Yoshinari Matsumoto, Daisuke Watanabe, Masashi Kato

  • Open Access

    Supplementary Figure Legend from Actin-Binding Protein, Espin: A Novel Metastatic Regulator for Melanoma

    by Takeshi Yanagishita, Ichiro Yajima, Mayuko Kumasaka, Yoshiyuki Kawamoto, Toyonori Tsuzuki, Yoshinari Matsumoto, Daisuke Watanabe, Masashi Kato